The aim of the randomized controlled clinical trial was to compare the efficacy of a 3-month regimen of isoniazid and pyrazinamide with that of a 6-month isoniazid in people living with HIV. Results: From the total 624 enrolled patients treatment was completed by 243 patients in short-course group and by 237 ones in IPT group (p=0,9). Adverse events were established in 6,1% of subjects in combined arm and in 6,7% in isoniazid group (p=0,8). After a follow-up 946,2 person-years, 8 person in isoniazid group and 9 person in compared group developed active TB with TB incidence per 100 person-years 1,9 and 1,8 respectively (p > 0,05). The Caplan-Meyer TB survival probability for the entire group of participants over the follow up period was 0,1306 without statistical differences. Three subjects were died in isoniazid group and one person - in combined group. Conclusion. Our data may suggest that for preventing tuberculosis in HIV-infected patients, a daily 3-month regimen of isoniazid and pyrazinamide is similar in safety and efficacy to a daily 6-month regimen of isoniazid. This shorter regimen offers practical advantages to patients and tuberculosis control programs, improving patients' adherence to TB prevention treatment.
Scopus subject areas
- Public Health, Environmental and Occupational Health
- Infectious Diseases